Preeclampsia remains one of the most formidable challenges in obstetrics. Affecting 5–10% of pregnancies worldwide, this hypertensive disorder is a leading cause of maternal and perinatal morbidity and mortality, second only to postpartum hemorrhage as a cause of maternal death . For decades, clinicians have relied on monitoring blood pressure and testing for protein in urine—signs that appear only after the disease has taken hold. However, a profound shift is underway. The discovery of specific biomarkers has opened a window into the health of the placenta long before symptoms arise. Among these, Placental Growth Factor (PlGF) has emerged as a powerful tool to predict, diagnose, and manage preeclampsia earlier and more accurately than ever before.
The Biology: What Is PlGF and Why Does It Matter?
To understand the significance of PlGF testing, one must first appreciate its role in a healthy pregnancy. PlGF is a protein belonging to the vascular endothelial growth factor (VEGF) family, and it plays a critical role in angiogenesis—the formation of new blood vessels . Throughout gestation, the placenta requires a robust and healthy network of blood vessels to supply the growing fetus with oxygen and nutrients. PlGF is a key driver of this process.
Outside of pregnancy, PlGF is nearly undetectable in the blood. As the placenta grows, maternal levels of PlGF rise steadily, peaking around 30 weeks before declining towards term . This predictable pattern is what makes it such a valuable indicator.
Preeclampsia is now understood to be a disease of the placenta. In its earliest stages, abnormal implantation leads to a poorly perfused, stressed placenta. In response, this dysfunctional placenta releases an excess of anti-angiogenic factors, most notably soluble Fms-like tyrosine kinase-1 (sFlt-1) . This molecule acts as a sponge, binding to and neutralizing pro-angiogenic factors like PlGF and VEGF . The result is a dramatic drop in the level of freely circulating PlGF in the mother’s blood. This angiogenic imbalance can be detected weeks before the onset of clinical symptoms such as high blood pressure and proteinuria, making PlGF an ideal early warning signal .
From Theory to Clinical Practice: Predicting Preeclampsia with PlGF
The primary clinical utility of PlGF lies in its ability to aid in both the prediction and diagnosis of preeclampsia, particularly in its most dangerous forms.
1. Early Prediction and Risk Assessment
One of the most exciting applications of PlGF is in the first trimester to identify women at high risk. Research has consistently shown that women who go on to develop early-onset preeclampsia have significantly lower serum concentrations of PlGF in early pregnancy compared to those with healthy pregnancies . A study published in Hebei Medicine found that low PlGF levels in early pregnancy demonstrated high predictive efficiency for early-onset preeclampsia, with an area under the ROC curve of 0.908, indicating excellent diagnostic accuracy .
This early warning allows for proactive management. The Fetal Medicine Foundation (FMF) recommends combining PlGF measurement with mean arterial pressure (MAP) and uterine artery pulsatility index (UT-PI) between 11 and 13+6 weeks of gestation . This combined model can achieve detection rates of 90% for early-onset preeclampsia and 75% for preterm preeclampsia, with a false positive rate of only 10% . For high-risk women identified through this process, organizations like the American College of Obstetricians and Gynecologists (ACOG) recommend prophylactic treatment with low-dose aspirin before 16 weeks to improve placental perfusion and significantly reduce the risk of preterm preeclampsia .
2. A Game-Changer in Special Populations
The value of PlGF is not limited to the general population. A groundbreaking study from Mount Sinai Hospital in Toronto demonstrated that PlGF can be a uniquely powerful predictor in pregnancies complicated by sickle cell disease (SCD) . Individuals with SCD face a doubled risk for placental complications. Researchers found that a PlGF cut-off of <100 pg/mL at 20–24 weeks’ gestation demonstrated an unprecedented 100% sensitivity and specificity for predicting early-onset preeclampsia in this high-risk group, outperforming thresholds used for other pregnancies .
The Diagnostic Power: Rule-Out and Rule-In
For women who present with symptoms of preeclampsia later in pregnancy (typically after 20 weeks), the PlGF test—often used in conjunction with the sFlt-1/PlGF ratio—has become an invaluable diagnostic adjunct.
The true strength of the test lies in its exceptional negative predictive value (NPV) . As explained in patient information from Cambridge University Hospitals NHS Foundation Trust, a negative result (defined as PlGF of 100 pg/mL or higher) provides significant reassurance: 98% of women with this result will not give birth due to preeclampsia within 14 days of the test . This allows clinicians to safely avoid unnecessary hospital admission and manage women with pregnancy hypertension on an outpatient basis .
Conversely, low results trigger escalating levels of concern and intervention:
- A result between 12 and 99 pg/mL suggests the placenta is not functioning well. It correctly identifies 95-96% of women with preeclampsia who will give birth within 14 days, warranting increased surveillance in a day care unit .
- A result of less than 12 pg/mL indicates a severely compromised placenta. It strongly predicts delivery within a short timeframe (on average 9 days if under 35 weeks) and necessitates immediate hospital admission for close monitoring of both mother and baby .
This stratification was confirmed by a large prospective study in Sierra Leone, which showed that point-of-care PlGF testing could accurately rule out serious outcomes like maternal death, eclampsia, and stillbirth, with very high NPVs .
Breaking Barriers: The Rise of Point-of-Care Testing
Historically, PlGF testing required sending blood samples to a laboratory for analysis, a process that could take hours or days and required sophisticated equipment. This posed a significant barrier in low- and middle-income countries (LMICs), where the burden of preeclampsia is highest .
That barrier is now crumbling. The development of novel, portable point-of-care (POC) devices, such as the RONIA and Lepzi Quanti tests, is revolutionizing access. These devices can measure PlGF from a single drop of whole blood (finger-prick sample) in as little as 15–30 minutes, without the need for centrifugation .
Studies validating these POC tests have shown they perform comparably to established laboratory tests, demonstrating high sensitivity and NPV for ruling out adverse outcomes . This technology means that accurate risk stratification can now be brought directly to the bedside in rural clinics and resource-constrained settings, enabling timely decisions about transfer to higher-level care or planned delivery .
Conclusion
Placental Growth Factor has moved from a scientific discovery to a cornerstone of modern prenatal care. By providing a direct window into placental function, PlGF testing empowers clinicians to move from a reactive stance—waiting for women to become ill—to a proactive one. It enables the early prediction of risk in the first trimester, facilitates the accurate diagnosis of preeclampsia in symptomatic women, and helps stratify those who need immediate intervention from those who can be safely monitored .
As point-of-care technology makes this test more accessible globally, its potential to save lives is immense . While it is not a standalone diagnostic tool and is most powerful when combined with clinical assessment and other indicators, PlGF has fundamentally changed the landscape of preeclampsia care. For the millions of women at risk, this simple blood test offers something unprecedented: a clear, early warning and a personalized roadmap for a safer pregnancy.
